JAPAN-SANITARY-EQUIP-IND
26.7.2022 04:02:07 CEST | Business Wire | Press release
The Japan Sanitary Equipment Industry Association, which is composed of Japanese companies engaged in the manufacturing of toilets (Headquarters: Nagoya, Aichi, Japan. President: Noriaki Kiyota [President & Representative Director of TOTO Ltd.], hereinafter “Association”) is proud to announce that the number of warm water spray seat shipments since the industry began tracking statistics (1987) has reached 100 million units as of June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005331/en/
The Road to 100 Million Units
The start of importation and sale of toilets and toilet seats with warm-water washing functionality into Japan in 1964 sparked major changes of “washing bottoms” in Japanese toilets. At first, sales were targeted towards medical facilities, and use was not widespread. Later, domestic production began, and companies launched initiatives including product development and improvement, and sales promotions to encourage use in common households. Eventually, more Japan residents grew to recognize these products after a TV commercial in 1982. Once people experienced the comfort of a warm toilet seat and the refreshing satisfaction of rear cleansing, they were unable to live without it. Good reputations spread, and these products finally became accepted by the general public.
Association member companies have been working continuously to evolve these products and to promote further use, by making new proposals and implementing updates that reflect consumer needs across multiple aspects, including function, comfort, hygiene, design, and energy efficiency. Currently in 2022, usage rates in general households have surpassed 80%, which means that it can finally be said that these products are estimated to be used in the majority of general households with flushable toilets. Likewise, because warm water spray seats have a good reputation for comfort, they have also been widely adopted for use in public places such as office buildings, commercial facilities, hotels, trains, and train stations.
Must-Have Item for Japanese Bathrooms
According to an awareness survey conducted by the Association in 2022 among warm water spray seat users in Japan, the main reason for use was “It’s sanitary and feels good to use.” In addition, 97% of the respondents would like to continue to use the warm-water washing toilet seats, indicating that once they use them, they find it so comfortable that they will not want to give them up.
Meanwhile, outside of Japan, demands are growing in other countries across the Americas, Europe, Asia, and the Middle East in recent years as interest in hygiene continues to rise, and the international market for warm water spray seats continues to expand every year. In particular, a sudden rise in demand was seen in North America in 2020, stoking anticipation for wider usage in the near future.
The Association and its members, Japanese manufacturers of warm water spray seats, are dedicated to making real improvements in restroom culture worldwide through the wider usage of sanitary and comfortable warm water spray seats in every country.
Awareness Survey for Warm Water Spray Seat Users
Survey Method: Online questionnaire
Survey Targets: Users of warm-water washing toilet seats, aged 10 to 79, living in Japan, 150 respondents for each age group, total of 2,100 respondents
Survey Period: February 4, 2022 (Friday) to February 7, 2022 (Sunday)
[ Survey Results Summary ]
The main reason for use was “It’s sanitary and feels good to use.”
When asked why they use warm water spray seats, most respondents said “It removes waste well and keeps me clean” (82%) and nearly half of respondents said “It feels good and refreshing” (48%).
97% of respondents said “I want to continue using it.”
Regarding their intention to continue the use of warm-water toilet seats in the future, 86% of respondents said they would like to continue to use them, and 11% said they would rather continue to use them.
Learn More About the Japan Sanitary Equipment Industry Association
The Japan Sanitary Equipment Industry Association is an industry organization made up of toilet equipment manufacturers that handle products such as sanitary fixtures (large and small toilets) and warm-water washing toilet seats.
The Japan Sanitary Equipment Industry Association operates the JAPAN TOILET INFORMATION website, which is dedicated to providing information on toilet conditions in Japan (usage, signage, etc.) for foreign visitors to Japan.
(https://www.sanitary-net.com/utsukushitoilet/en/
)
[ Member Companies (As of June 2022, in alphabetical order) ]
Aisin Corporation, Asahi Eito Co., Ltd., Janis Ltd., Lixil Corporation, Panasonic Holdings Corporation, SAN-EI Faucet Mfg Co., Ltd, Toshiba Lifestyle Products & Services Corporation, TOTO Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
